Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This study found that spironolactone effectively reduced hair growth in hirsute women over 12 months and was generally well tolerated.

This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

In this study, Buserelin nasal spray significantly reduced hirsutism scores and suppressed ovarian steroid secretion in women with non-adrenal hirsutism over six months, with effects lasting post-treatment.

This abstract reviews the use of spironolactone as a treatment for hormonal acne, female pattern hair loss, and hirsutism due to its antiandrogenic properties and favorable side effect profile, highlighting its value in dermatological therapies.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This study found that both spironolactone with Ovysmen and cyproterone acetate with ethinyloestradiol significantly reduced hair growth in hirsute women, with no difference in effect between treatments.

This article discusses the underutilization of spironolactone in dermatology for conditions like acne, highlighting its potential benefits and good safety profile, but reports no new clinical findings.

This review found some evidence suggesting that spironolactone can effectively reduce hirsutism in women but did not support its use for treating acne vulgaris.

In this study, spironolactone treatment reduced hair growth in 17 out of 30 patients with hirsutism, but was less effective compared to cyproterone acetate–estrogen therapy.

This study observed that microneedling induced significant hair regrowth and reduced hyperpigmentation in two Pomeranians with alopecia X, with stable results over 12 months.

This study identified the expression of 5αR1 and 5αR3 enzymes in canine skin, which may advance understanding and treatment of alopecia X.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study found that ovarian suppression significantly reduced serum testosterone and androstenedione in women with polycystic ovarian syndrome and idiopathic hirsutism, with hair growth rates decreasing more in polycystic ovarian syndrome.

This research reported that liposomal systems made from pig-derived skin lipids enhanced finasteride delivery to hair follicles for treating androgenetic alopecia, showing improved drug deposition, hair length, and growth compared to conventional finasteride forms in vitro.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This article discusses hyperandrogenism syndrome in women, highlighting systemic antiandrogenic therapy as advisable for severe or moderate hirsutism but reports no new clinical results.

Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.

This source suggests that spironolactone, a potassium-sparing diuretic, is underutilized in dermatology despite evidence showing its potential benefits for female acne, hidradenitis suppurativa, and female androgenetic alopecia, noting its long-term safety and reduced need for additional testing in young women.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study found that allopregnanolone has a bimodal effect on prolactin secretion in sheep, stimulating PRL mRNA expression but inhibiting hormone release under stress and pregnancy conditions.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

In this study, elevated prolactin and DHEA-S levels along with reduced SBP were observed in fertile non-obese women with moderate body hair compared to controls, and ethynylestradiol plus desogestrel or cyproterone acetate treatment improved clinical outcomes by increasing SBP.

This study found that in hirsute women, daily treatment with 200 mg spironolactone significantly reduced hair growth rates and hair shaft diameters on various body areas over 12 months.

This study found that polymeric micelle nanocarriers delivered pharmacologically relevant amounts of spironolactone to the epidermis and upper dermis, with higher delivery to pilosebaceous units, suggesting potential for treating glucocorticoid-induced impaired wound healing and pilosebaceous androgen-related skin diseases.

This case study describes a 15-year-old girl with a Sertoli–Leydig cell tumor who showed high androgen levels and steroidogenic responses similar to patients with polycystic ovary syndrome before surgery.